Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial

ConclusionPatients with stage III NSCLC and a large MTV in whom definitive RCT had a particularly good survival in the ESPATUE trial. Treatment individualization according to MTV is not supported by this study. The ESPATUE and ACRIN trials differed by the use of cisplatin-containing induction chemotherapy and an intensified radiotherapy regimen that were particularly effective in patients with large MTV disease.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research

Related Links:

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide, with 2.1 million new lung cancer cases and 1.8 million deaths per year [1 –4]. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Up to 61% of patients have advanced disease at the time of diagnosis, with a 5-year survival rate of 18% [5,6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
We describe here a case of 48 y.o. male patient with ALK-positive NSCLC who was clinically managed for 6.5 years from the diagnosis. The tumor was surgically resected, but 8 months later multiple brain metastases were discovered. The patient started receiving platinum-based chemotherapy and then was enrolled in a clinical trial of second-generation ALK inhibitor ceritinib, which resulted in a 21 months stabilization. Following disease relapse, the patient was successfully managed for 33 months with different lines of chemo- and local ablative therapies. Chemotherapy regimens, including off-label combination of crizotinib +...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionCeritinib showed higher efficacy associated with a better control of systemic progression compared to crizotinib for the front ‐line treatment of ALK‐positive advanced NSCLCs.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are aggressive neuroendocrine tumors with poor survival rates [1 –3]. For stage IV SCLC, treatment has not advanced significantly over the last decades and consists of palliative chemotherapy. The same applies to stage IV LCNEC, were no standard treatment exists and palliative chemotherapy with SCLC and non-small cell lung cancer (NSCLC) regimens are both deeme d appropriate [4]. Recently, targeted therapy focusing on delta like protein 3 (DLL3) has received attention to improve outcomes for SCLC and LCNEC [5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: December 2019Source: Biomedicine &Pharmacotherapy, Volume 120Author(s): Yang Li, Yayun Wu, Qi Xia, Ya Zhao, Ruizhi Zhao, Shigui DengAbstractCisplatin (DDP) is a first-line drug for non-small cell lung cancer (NSCLC), but its efficacy and applications are constrained by intolerance and serious side effects. Platycodon grandiflorus (PG) is usually used as lung medicinal drug to enhance other drug’s effect on lung diseases. Therefore, present study aim to investigate anti-NSCLC effect of PG with DDP and mechanism involved in the combination for the first time. The results showed that compared with ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Abstract Background: Patients with unresectable locally advanced NSCLC who refuse or are not candidates for chemotherapy often receive radiation therapy (RT) alone. Hypofractionated RT (HFRT) regimens are becoming increasingly common. An analysis of the National Cancer Database (NCDB) was performed to evaluate the practice patterns and outcomes of HFRT vs. conventionally fractionated RT (CFRT) in patients with stage III NSCLC undergoing definitive RT alone. Material and methods: The NCDB was queried for all patients with stage III NSCLC diagnosed between 2004 and 2014 who received RT alone. CFRT was defined as pat...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Conclusion: Data from our study suggest nivolumab is well-tolerated and effective in Indian patients with recurrent advanced NSCLC after failure of the multiple first lines of platinum-based combination chemotherapy.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study investigated the reversal effect of PL both in vitro and in vivo, and provided evidence that PL inhibited the phosphorylation of Akt via the accumulation of reactive oxygen species in chemotherapy resistance cells. Consequently, various Akt activation-dependent genes caused a reduction of drug efflux and induction of apoptosis in cisplatin-resistant A549 NSCLC cells. Our results indicate that Akt phosphorylation may play a functional role in the reversal effect of PL and contribute, at least in part, to the treatment outcomes of patients with chemotherapy resistance.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Abstract Cisplatin (DDP) is a first-line drug for non-small cell lung cancer (NSCLC), but its efficacy and applications are constrained by intolerance and serious side effects. Platycodon grandiflorus (PG) is usually used as lung medicinal drug to enhance other drug's effect on lung diseases. Therefore, present study aim to investigate anti-NSCLC effect of PG with DDP and mechanism involved in the combination for the first time. The results showed that compared with DDP group, the combined groups (DDP combined with 1, 2 and 4 g/kg of PG) reduced the tumor luminescence density by 26.0%, 78.2% and 32.8% respective...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
Conclusions: The usefulness of RCTs for estimating the costs of AEs may be improved by using a standardized form to collect HCRU data for key AEs, including an appropriate level of detail required to estimate costs of managing the AEs. PMID: 31595803 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Germany Health | Lung Cancer | Non-Small Cell Lung Cancer | Nuclear Medicine | Study